Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

Debbie Shawcross

Secretary General

UK

Debbie Shawcross is a Clinician Scientist and Professor of Hepatology and Chronic Liver Failure at the Roger Williams Institute of Liver Studies, King’s College London. She works as a Consultant Hepatologist on the King’s College Hospital Liver Unit with a specialist interest in hepatic encephalopathy and the complications of cirrhosis. She was elected to the EASL Scientific Committee and Governing Board in October 2022 and is an advocate for high quality education and training in gastroenterology and hepatology having been a Health Education England London Gastroenterology Training Programme Director for 10 years serving on the British Society Gastroenterology (BSG) Specialist Advisory Committee and Training Committee, BSG Mentor and an active member of the BSG Supporting Women in Gastroenterology. She is Chair of the BSG Research Committee, Clinical Advisor for the British Liver Trust and a Trustee for GUTS UK Charity.

Her research programme characterises the immunobiology of chronic liver failure focusing specifically on the gut-liver-brain axis in the context of the gut microbiome as a driver of immune dysfunction, inflammation and encephalopathy. She is leading the field in clinical trials of faecal microbiota transplantation (FMT) in Europe and is Chief Investigator of the NIHR-funded EME UK multicentre randomised placebo-controlled clinical trial of FMT (capsules) [PROMISE Trial] in patients with metabolic dysfunction-associated and alcohol-related cirrhosis.

Scroll to Top

Search EASL